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ABSTRACT 
This review highlights the microbiota gut-brain axis and neurodegenerative diseases 
excluding studies on animal models. Gut microbiota is capable of modulating some 
brain activities via the microbiota gut-brain axis. A bidirectional communication exists 
between the gastrointestinal (GI) tract and the central nervous system (CNS) in the 
microbiota gut-brain axis. Gut dysbiosis has been linked to neurodegenerative 
diseases as a result of the imbalance in the composition of its microbiota, which has 
a damaging effect on the host’s health. The association between the role and 
mechanism of CNS disease and gut microbial is yet to be fully explored. Although 
some studies have shown a positive relationship between a rich diverse microbial 
community and the brain of the host, and a negative relationship between microbial 
dysbiosis, intestinal infection and human brain health, our knowledge, however, is 
limited due to the inability to identify the major players in this heterogeneous 
microbial community. 
 
 
INTRODUCTION 
Clinicians and biomedical researchers have shown great interest in the 
role of gut microbe function and the central nervous system (CNS), 
mainly in the modulation of cholecystokinin. However, this has been 
extended to a generalized description; the microbiota gut –brain axis 
especially in its link to neurodegenerative disease.1 The human body 
and its microbial community such as the skin, vaginal mucosa, oral 
mucosa and most importantly the gut, co-exist in a symbiotic relation- 
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ship. This relationship plays a vital role in health and 
neurodegenerative diseases.2 Microbiome is 
inherited maternally during vaginal delivery through 
the vaginal fluid enriched with microbiota. This 
becomes a major player of immune defense and 
eventually becomes modified to suit the individual’s 
unique composition.3,4 
Microbiota concentration is highest in the gut of 
the human body.5 This can be a source of energy for 
cells as they provide essential micro nutrients such 
as thiamine, vitamins A, B, D and K. They also provide 
nutrients in form of short chain fatty acids (SCFAs) 
like acetate, propionate, and butyrate; as the 
ultimate energy source for colonocytes. When SCFAs 
like butyrate, acetate, and propionate are stimulated, 
it could result in an increased production of 
immunoglobulin (IgG).6 Gut microbiota also serves as 
a barricade between humans and their environment 
especially in the protection of environmental 
hazards3 and when it is disease-free, can prolong the 
lifespan of humans.6 
Disruptions of gut microbiota barrier can lead to 
many diseases.7  It was previously considered stable 
and unique for each individual but has now been 
reported to have long lasting changes.1 This could be 
secondary to pathophysiological disruption of short 
intraluminal regulatory loop that leads to major 
dysfunction of various cells and microflora, thus, 
affecting the enteric nervous system(ENS) within the 
submucosal and muscularis layers of the colon.8  
Gut dysbiosis has been linked to 
neurodegenerative diseases as a result of the 
imbalance in its composition which alters and causes 
damaging effect on the host’s health.9 
The aim of this review is to highlight the 
microbiota gut-brain axis and functional linkages to 
neurodegenerative diseases such as Alzheimer’s 
disease (AD), Amyotrophic lateral sclerosis (ALS) and 
Parkinson Disease (PD), excluding animal models.  
 
DISCUSSION 
Communication between gut microbiota and the 
development of the central nervous system 
(CNS) 
Microbiota which consists of bacteria, viruses, fungi 
and other microorganisms can alter adult 
hippocampus neurogenesis (AHN), thus affecting the 
pathogenesis of symptoms of diseases of CNS.7,10 It 
helps in the permeability and maintenance of the 
blood brain barrier (BBB) and is important in the 
maturation of glia cells of the CNS. The absence of a 
complex host microbiota could result in an altered 
glial cells number, a decrease in permeability and 
could halt the development of the blood brain 
barrier, thus, causing an impaired immune response 
resulting in CNS disease.11 
Although, invasive pathogen by microbes is not 
the only route to the aetiology of neurodegenerative 
diseases, it has a systemic impact on the microbiota 
community via the enteric nervous system, immune 
system, blood stream, intercellular signaling and the 
vagus nerve.5 
 
The Microbiome Gut-Brain Axis 
The association between the role and mechanism of 
CNS disease and gut microbial have yet to be fully 
explored.11 A bidirectional communication exists 
between the gastrointestinal (GI) tract and the 
central nervous system (CNS) in the microbiota gut-
brain axis. This is effective under physiological 
conditions in immune defense, digestive system 
modulation, perception and sensory response to 
visceral stimuli, secondary to its incorporation to the 
CNS, neuroendocrine and neuroimmune systems, 
autonomic nervous system (ANS) and enteric 
nervous system (ENS).3 Studies have reported four 
key section to the gut-brain axis, these include: 
activation of the immune defense, neuroendocrine 
pathways regulation, autonomic sensorimotor 
connections and lastly, the interaction between the 
blood brain barrier and gut microbiota metabolites.2 
Microbially derived molecules such as short-chain 
fatty acids (SCFAs), secondary bile acids, and 
tryptophan metabolites mediate the communication 
of microbes and the CNS, although CNS modulation 
via neuroimmune and neuroendocrine mechanisms 
interacts with enterochromaffin cells, mucosal 
immune system and enteroendocrine cell and 
sometimes enters the systemic circulation  and 
penetrates the blood-brain barrier, it still remains 
difficult to ascertain if they induce responses only or  
get to the  brain directly via long-distance neural 
signaling with vagal and/or afferents from the spinal 
cord.12 SCFA are the main microbial mediators in the 
gut–brain axis.2 SCFA are released from action of 
microbiota in the gut which are further metabolized 
by intestinal absorption and finally removed through 
urination.11 
The gut microbiome harbours 150 times more 
genes than the human genome.2 They are 
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heterogeneous group of bacterial species, fungi and 
viruses found in the gastrointestinal tract having a 
symbiotic relationship with the human host. The 
microbiome plays an important function in 
metabolism, blood-brain barrier integrity, immune 
defense, secretion, maintaining homeostatic balance 
of barrier integrity and coordinating the transfers of 
signals through primary afferent pathway of the 
vagus nerve to the CNS via the gut-brain axis. The 
vagus nerves serves as the primary afferent pathway 
for various factors influencing the formation of 
microbiota, these include: medications, lactation, 
ingested meal and parturition.11 
The use of functional imaging, for example, 
functional magnetic resonance imaging (fMRI) and 
Positron emission tomography (PET) revealed resting 
brain function alteration in patients with functional 
gastrointestinal disorders, via the possibility of gut-
brain axis dysfunction.13 
Intriguingly, the concept that microbiome 
influences the gut-brain axis may seem debatable 
but it is used routinely by clinician to treat patients. 
For instance, the use of oral antibiotics medication 
and laxatives for treatment of patients with altered 
mental state secondary to hepatic encephalopathy.1 
 
 
Figure 1. Bidirectional interactions of four key sections in the 
gut-brain axis12. 
 
The Gut Microbiota in Neurodegenerative 
disorders 
The aetiology of most neurodegenerative diseases 
are multifactorial and speculative, there is possibility 
that the apotheosis of these mechanism of gut 
microbiome-host symbiotic relationship contribute 
to a large extent to the disease pathogenesis in the 
genetically-predisposed.14 Microbiota research on 
neurodegenerative diseases is still in the infancy 
stage, interestingly, recent studies have linked the 
potential role of the gut-microbiota axis on central 
nervous system (CNS) related conditions and its 
influence on the gut brain axis. 5,7,11 Chronic 
neuroinflammation is a unique feature associated 
with the pathology of most neurodegenerative 
diseases (ALS, PD, AD).6 Although, bacterial toxin has 
been linked to the aetiology of neurodegenerative 
disease, systemic inflammation and its infectious 
burden is suggested to be the prime factor that 
predisposes to neurodegeneration or immune 
response of the host to gut dysbiosis rather than an 
isolated single infectious agent. This inflammation is 
the initial stimulus to the neuropathological cascade 
seen in neurodegenerative disease that drifts 
gradually along the sacral autonomic nerves and 
dorsal motor nucleus of the vagus nerves, to the 
midbrain cortex through trans-synaptic spread and 
hence degeneration of the CNS.5,14 Gut mucosa 
lymphocytes secrete pro-inflammatory mediators 
which causes protein misfolding in neighbouring 
enteric neurons. This is the main cause of 
pathogenesis seen in neurodegenerative disease 
such as AD and PD.14 
Although, bacteria causes misfold of amyloid 
protein as seen in Alzheimer’s disease (AD) and 
Parkinson disease (PD), aggravating oxidative stress, 
neuroinflammation and progressive 
neurodegeneration, neurodegeneration could also 
provide a favourable atmosphere for the growth of 
microbes via the micro-environmental change 5,6 
Spirochetes, herpes simplex virus type 1 and 
chlamydophila pneumoniae infections have been 
associated with the brain of AD patients and fungal 
infection in both AD and Amyotrophic lateral 
sclerosis (ALS).5 Prion-like transmission through 
molecular mimicry pathway suggests that 
microbiota is vital in prion-like transmission seen in 
neurodegenerative disease.10 Minuit quantities of 
cyanobacteria which produce β-N-methyl amino-L-
alanine (BMAA) are reported to be increased in the 
brain of patients with AD, PD and amyotrophic lateral 
sclerosis (ALS). This has been linked to the misfolding 
of proteins and aggregation seen in 
neurodegenerative disease.3  
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Constipation is a common symptom in PD, this is 
likely due to neurodegeneration of autonomic 
centers of the enteric nervous system (ENS).9 Urinary 
tract infection is also a common symptom seen in 
neurodegenerative disease especially in AD and PD. 
A variety of microbes have been identified in healthy 
urinary tracts using novel laboratory culture 
methods, this could be linked to the immune system 
modulation. Interestingly, microbiome found in the 
skin have been suggested to be linked to 
microbiological and amyloid axis between the skin 
and the brain, but no detailed evidence has been 
reported.14 
While research has focused on neural and 
inflammatory signaling, the future role of circulating 
metabolites of gut microbe-has been under-
explored.2 
 
 
Figure 2. Interaction between gut microbiota and 
neurodegenerative disorders15. 
 
Gut Microbiota and Alzheimer’s disease (AD) 
AD is a progressive degenerative neurological 
disease with intracellular neurofibrillary tangles, 
extracellular β-amyloid (Aβ) and senile plaques.7 No 
detailed study on the interaction of gut microbiota 
and alzheimer’s disease has been reported5, 
however a study reported the gut microbiota 
imbalance and the development of AD as a result of   
inflammation and increasing the permeability of the 
intestine and endothelium.6,7  High levels of 
inflammatory markers, total and phosphorylated tau 
protein have been reported in AD patient with 
Helicobacter pylori (H. Pylori) infection.6 Studies have 
also linked the association of serum antibodies and 
AD and a reduction in brain-derived neutrophilic 
factor (BDNF).5,7 High levels of inflammatory markers 
(as shown in figure 3), total and phosphorylated tau 
protein have been reported in AD patient with 
Helicobacter pylori (H. Pylori) infection.6   
Gut microbial diversity is reduced in patient with 
Alzheimer’s disease (AD). Patients with AD show an 
increase in intestinal bacteria such as Bacteroides, 
Bacteroidetes resulting in an exaggerated 
translocation of Lipopolysaccharide (LPS) to the CNS 
from the gut. This would in turn cause 
neuroinflammation and exacerbate AD, while a 
decrease in Bifidobacterium, Firmicutes seen in AD 
patients is associated with a decrease in permeability 
of the intestine.11 Excessive high fat diet, for example 
corn oil causes an alteration in the composition of 
gut microbiota thereby increasing intestinal 
permeability. This is associated with an increased 
risk of AD, however diet containing n-3 
polyunsaturated fatty acids have not been linked to 
AD. Intestinal microbial metabolites of dietary fats 
for example Trimethylamine N-oxide(TMAO) can 
serve as a biomarker for AD,  which supports the 
association of excessive high fat diet meal seen in 
western diet with AD.6 
Intriguingly, although gut microbiota such as E. 
coli, Bacillus subtilis, Mycobacterium tuberculosis, 
Staphylococcus aureus, Salmonella typhimurium, and 
Salmonella enterica, and fungi are capable of 
secreting amyloid (resulting in a rise of CNS amyloid 
levels distorting the dynamic amyloid protein 
causing aggregation in the brain and a high risk in 
AD), they are also able to reduce amyloid of patients 
with AD via an indirect diet-mediated mechanism. 
For example Bacillus spp and Lactobacillus spp 
produces acetylcholine, a deficient neurotransmitter 
in AD.6, 7 
 
 
Figure 3. Interaction between gut microbiota and 
inflammatory markers in the pathogenesis of AD6. Tumour 
necrosis factor (TNF), triggering receptor expressed on myeloid 
cells-2 (TREM2,), zonula occludens (ZO), interleukins (IL), 
lipopolysaccharide (LPS). 
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Gut Microbiota and Amyotrophic Lateral 
sclerosis (ALS) 
ALS is a progressive degenerative disorder that 
affects the brain and spinal cord neurons, it is a 
multi-system disorder that affects the 
gastrointestinal tract which could be as a result of the 
increased permeability of the intestine that would 
increase circulating lipopolysaccharide (LPS).6, 10 
Chronic neuroinflammation and microglial activation 
are features of ALS.6 The pathogenesis of ALS 
involves increase circulating LPS (derived from gram-
negative bacteria cell walls) and innate immune 
response, suggesting a concept of gut-derived 
neurotoxins. Tight junction proteins (occludin, VE-
cadherin/CD144) and the junction adhesion 
molecule (JAM)) in the lumber spine are reduced 
leading to the disruption of the blood-spine cord 
barrier (BSCB) and blood brain barrier (BBB) in 
patients with ALS thus, facilitating permeability and 
increased exposed of motor neurons to the toxic 
substance released from the gut (Figure 
4).Dysfunction of intestinal barrier can lead to the 
passage of toxins to the blood from the lumen of the 
intestine.10 Constipation is a common symptom in 
ALS, however details about the effect of changes in 
the gut microflora on gastrointestinal motility in ALS 
patients seem skeptical.6,10 
In a nutshell, research on the dynamics and 
relationship of gut microbiota and the stages of ALS 
is limited.10 
 
 
 
Figure 4. Interaction between gut microbiota and the 
pathogenesis of ALS6. Tumour necrosis factor (TNF), 
cyclooxygenase (COX), interleukin (IL), vascular endothelial (VE), 
zonula occludens (ZO). 
Gut Microbiota and Parkinson Disease (PD) 
The loss of dopamine neurons in the substantia 
nigra, aggregation of misfolded protein (α-synuclein), 
calcium overload, mitochondrial dysfunction and 
oxidative stress account for most of the 
pathogenesis seen in PD.11 
Although, there is inadequate information on the 
microbiota-host relationship in PD5, recent studies 
have shown the role of gut microbiota bi-directional 
communications between gut and brain in the 
pathogenesis of PD. Studies have reported over 
expression of protein inclusions (α-synuclein) 
causing misfolding and  aggregation in PD,3 which  
reaches the brain via the glossopharyngeal and 
vagus nerves.11 Interestingly, misfold and 
aggregation of α-synuclein is not specific to PD, there 
is a descending gradient in the frequency of amount 
of lewy bodies seen in the GI tract. This ranges from 
submandibular gland with the highest frequency, to 
lower oesophagus, stomach, small intestine, large 
intestine and rectum with the lowest frequency. The 
vagal innervation from the dorsal motor nucleus of 
the vagus nerve (DMNV) and the enteric nervous 
system (ENS) dopaminergic neurons distribution 
coincide with the descending gradient of the amount 
of lewy body’s pathology.9 
A clinical staging system of PD (Braak stages) 
proposes that the genesis of neurodegenerative 
disease is via a dual-hit mechanism in which the 
neurodegenerative process starts in the olfactory 
bulb following inhalation and in the ENS of the gut 
secondary to neurotropic pathogen ingestion. This 
later advances forward to the temporal lobe from 
the olfactory bulb and backward to the 
intermediolateral nucleus (IML) cord or dorsal motor 
nucleus of the vagus (DMNV) and then to the brain 
stem from the gut through the sympathetic and 
parasympathetic nerves respectively as illustrated in 
Figure 5. 
Gut microbiota dysbiosis have been linked to 
patients with PD and increased incidence of small 
intestinal bacteria overgrowth (SIBO) compared to 
control.3,11Over-proliferation of gut microbiota alters 
intestinal motility.16 Constipation is a common and 
early symptom of PD, and can be as a result of 
prolong intestinal transit time secondary to impaired 
colonic motility.9 It is 2 times more prevalent in 
patients with PD compared to control, and a 2 times 
probability of individuals with constipation having PD 
within 10 years.3 Intriguingly, a high prevalence of 
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Helicobacter pylori (H. Pylori) infection has been 
reported in patient with PD.9 Studies have linked 
changes in intrinsic ratios of gut microbiota fecal 
specimens with PD.8 The faecal samples of patients 
with PD shows an increase in bacteria such as 
Lactobacillus and a decrease in Prevotella, Clostridium 
coccoides and Bacteroides fragilis faecal samples. The 
decrease Prevotella counts is associated with an 
increase in permeability of the gut and a decrease in 
synthesis of mucin. Although Prevotella counts is not 
unique to the diagnosis of PD alone, the hydrogen 
sulfide they secrete is reported to have a protective 
effect on dopaminergic neurons.11 Studies have also 
reported an abundance of Enterobacteriaceae count 
isolated from faecal sample in patients with gait 
anomaly and postural instability, suggesting a link of 
microbiota to the PD. Further research on the early 
communication between gut microbiota and PD 
would give new useful insights in the intervention for 
diagnosing and treating patients with PD.11 
 
 
Figure 5. Genesis of neurodegenerative disease via dual-hit 
mechanism involving the olfactory bulb and ENS9. 
 
CONCLUSION 
Gut microbiota is capable of modulating some brain 
activities via the microbiota gut-brain axis. Although, 
studies have shown a positive relationship between 
rich diverse microbial community and the brain of 
the host, and a negative relationship between 
microbial dysbiosis, intestinal infection and human 
brain health, our knowledge however, is limited due 
to the inability to identity the major players in this 
heterogeneous microbial community. These findings 
are particularly promising in finding out if microbiota 
changes precede or succeed the pathogenesis seen 
in neurodegenerative disease.6 This review excluded 
literatures on evidence from animal and 
pharmacological models which some other previous 
studies focused. Although animal models can be 
controlled experimentally, this microbial community 
can be easily misrepresented or missed when 
scanning for total composition of the microbiota 
composition. Besides, reduced diversity in 
microbiota population is seen more in animal 
models compared to humans. 
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ABBREVIATIONS 
AD: Alzhemier’s disease 
AHN: Adult hippocampus neurogenesis  
ALS: Amyotrophic lateral sclerosis 
ANS: Autonomic nervous system  
BBB: Blood brain barrier  
BDNF: Brain derived neurotrophic factor 
BMAA: β-N-methyl amino-L-alanine  
BSCB: Blood-spinal cord barrier 
CNS: Central nervous system 
COX: Cyclooxygenase 
ENS: Enteric nervous system  
fMRI: Functional magnetic resonance imaging 
GI: Gastrointestinal   
IL:  Interleukin 
JAM:Junction adhesion molecule  
LPS: Lipopolysaccharide  
PD: Parkinson disease 
PET: Positron emission tomography 
SCFAs: Short chain fatty acids  
SIBO: Small intestinal bacteria overgrowth  
TMAO: Trimethylamine N-oxide  
TNF: Tissue necrosis factor 
TREM2:  Triggering receptor expressed on myeloid cells-2  
ZO: Zonula occludens 
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